journal
MENU ▼
Read by QxMD icon Read
search

Kidney International Supplements

journal
https://read.qxmd.com/read/30828481/china-kidney-disease-network-ck-net-2015-annual-data-report
#1
Luxia Zhang, Ming-Hui Zhao, Li Zuo, Yue Wang, Feng Yu, Hong Zhang, Haibo Wang
No abstract text is available yet for this article.
March 2019: Kidney International Supplements
https://read.qxmd.com/read/30675443/kdigo-2018-clinical-practice-guideline-for-the-prevention-diagnosis-evaluation-and-treatment-of-hepatitis-c-in-chronic-kidney-disease
#2
(no author information available yet)
No abstract text is available yet for this article.
October 2018: Kidney International Supplements
https://read.qxmd.com/read/30675442/global-capacity-for-clinical-research-in-nephrology-a-survey-by-the-international-society-of-nephrology
#3
REVIEW
Ikechi G Okpechi, Mona Alrukhaimi, Gloria E Ashuntantang, Ezequiel Bellorin-Font, Mohammed Benghanem Gharbi, Branko Braam, John Feehally, David C Harris, Vivekanand Jha, Kailash Jindal, David W Johnson, Kamyar Kalantar-Zadeh, Rumeyza Kazancioglu, Adeera Levin, Meaghan Lunney, Timothy Olusegun Olanrewaju, Vlado Perkovic, Jeffrey Perl, Harun Ur Rashid, Eric Rondeau, Babatunde Lawal Salako, Arian Samimi, Laura Sola, Irma Tchokhonelidze, Natasha Wiebe, Chih-Wei Yang, Feng Ye, Alexander Zemchenkov, Ming-Hui Zhao, Aminu K Bello
Due to the worldwide rising prevalence of chronic kidney disease (CKD), there is a need to develop strategies through well-designed clinical studies to guide decision making and improve delivery of care to CKD patients. A cross-sectional survey was conducted based on the International Society of Nephrology Global Kidney Health Atlas data. For this study, the survey assessed the capacity of various countries and world regions in participating in and conducting kidney research. Availability of national funding for clinical trials was low (27%, n  = 31), with the lowest figures obtained from Africa (7%, n  = 2) and South Asia (0%), whereas high-income countries in North America and Europe had the highest participation in clinical trials...
February 2018: Kidney International Supplements
https://read.qxmd.com/read/30675441/global-coverage-of-health-information-systems-for-kidney-disease-availability-challenges-and-opportunities-for-development
#4
REVIEW
Emily J See, Mona Alrukhaimi, Gloria E Ashuntantang, Aminu K Bello, Ezequiel Bellorin-Font, Mohammed Benghanem Gharbi, Branko Braam, John Feehally, David C Harris, Vivekanand Jha, Kailash Jindal, Kamyar Kalantar-Zadeh, Rumeyza Kazancioglu, Adeera Levin, Meaghan Lunney, Ikechi G Okpechi, Timothy Olusegun Olanrewaju, Mohamed A Osman, Jeffrey Perl, Bilal Qarni, Harun Ur Rashid, Ahmed Rateb, Eric Rondeau, Arian Samimi, Majid L N Sikosana, Laura Sola, Irma Tchokhonelidze, Natasha Wiebe, Chih-Wei Yang, Feng Ye, Alexander Zemchenkov, Ming-Hui Zhao, David W Johnson
Development and planning of health care services requires robust health information systems to define the burden of disease, inform policy development, and identify opportunities to improve service provision. The global coverage of kidney disease health information systems has not been well reported, despite their potential to enhance care. As part of the Global Kidney Health Atlas, a cross-sectional survey conducted by the International Society of Nephrology, data were collected from 117 United Nations member states on the coverage and scope of kidney disease health information systems and surveillance practices...
February 2018: Kidney International Supplements
https://read.qxmd.com/read/30675440/global-access-of-patients-with-kidney-disease-to-health-technologies-and-medications-findings-from-the-global-kidney-health-atlas-project
#5
REVIEW
Htay Htay, Mona Alrukhaimi, Gloria E Ashuntantang, Aminu K Bello, Ezequiel Bellorin-Font, Mohammed Benghanem Gharbi, Branko Braam, John Feehally, David C Harris, Vivekanand Jha, Kailash Jindal, Kamyar Kalantar-Zadeh, Rumeyza Kazancioglu, Peter G Kerr, Adeera Levin, Meaghan Lunney, Ikechi G Okpechi, Michelle E Olah, Timothy Olusegun Olanrewaju, Mohamed A Osman, Yasin Parpia, Jeffrey Perl, Bilal Qarni, Harun Ur Rashid, Ahmed Rateb, Eric Rondeau, Babatunde Lawal Salako, Laura Sola, Irma Tchokhonelidze, Marcello Tonelli, Natasha Wiebe, Isaac Wirzba, Chih-Wei Yang, Feng Ye, Alexander Zemchenkov, Ming-Hui Zhao, David W Johnson
Access to essential medications and health products is critical to effective management of kidney disease. Using data from the ISN Global Kidney Health Atlas multinational cross-sectional survey, global access of patients with kidney disease to essential medications and health products was examined. Overall, 125 countries participated, with 118 countries, composing 91.5% of the world's population, providing data on this domain. Most countries were unable to access eGFR and albuminuria in their primary care settings...
February 2018: Kidney International Supplements
https://read.qxmd.com/read/30675439/global-nephrology-workforce-gaps-and-opportunities-toward-a-sustainable-kidney-care-system
#6
REVIEW
Mohamed A Osman, Mona Alrukhaimi, Gloria E Ashuntantang, Ezequiel Bellorin-Font, Mohammed Benghanem Gharbi, Branko Braam, Mark Courtney, John Feehally, David C Harris, Vivekanand Jha, Kailash Jindal, David W Johnson, Kamyar Kalantar-Zadeh, Rumeyza Kazancioglu, Scott Klarenbach, Adeera Levin, Meaghan Lunney, Ikechi G Okpechi, Timothy Olusegun Olanrewaju, Jeffrey Perl, Harun Ur Rashid, Eric Rondeau, Babatunde Lawal Salako, Arian Samimi, Laura Sola, Irma Tchokhonelidze, Natasha Wiebe, Chih-Wei Yang, Feng Ye, Alexander Zemchenkov, Ming-Hui Zhao, Aminu K Bello
The health workforce is the cornerstone of any health care system. An adequately trained and sufficiently staffed workforce is essential to reach universal health coverage. In particular, a nephrology workforce is critical to meet the growing worldwide burden of kidney disease. Despite some attempts, the global nephrology workforce and training capacity remains widely unknown. This multinational cross-sectional survey was part of the Global Kidney Health Atlas project, a new initiative administered by the International Society of Nephrology (ISN)...
February 2018: Kidney International Supplements
https://read.qxmd.com/read/30675438/global-overview-of-health-systems-oversight-and-financing-for-kidney-care
#7
REVIEW
Aminu K Bello, Mona Alrukhaimi, Gloria E Ashuntantang, Ezequiel Bellorin-Font, Mohammed Benghanem Gharbi, Branko Braam, John Feehally, David C Harris, Vivekanand Jha, Kailash Jindal, David W Johnson, Kamyar Kalantar-Zadeh, Rumeyza Kazancioglu, Peter G Kerr, Meaghan Lunney, Timothy Olusegun Olanrewaju, Mohamed A Osman, Jeffrey Perl, Harun Ur Rashid, Ahmed Rateb, Eric Rondeau, Aminu Muhammad Sakajiki, Arian Samimi, Laura Sola, Irma Tchokhonelidze, Natasha Wiebe, Chih-Wei Yang, Feng Ye, Alexander Zemchenkov, Ming-Hui Zhao, Adeera Levin
Reliable governance and health financing are critical to the abilities of health systems in different countries to sustainably meet the health needs of their peoples, including those with kidney disease. A comprehensive understanding of existing systems and infrastructure is therefore necessary to globally identify gaps in kidney care and prioritize areas for improvement. This multinational, cross-sectional survey, conducted by the ISN as part of the Global Kidney Health Atlas, examined the oversight, financing, and perceived quality of infrastructure for kidney care across the world...
February 2018: Kidney International Supplements
https://read.qxmd.com/read/30675437/guidelines-policies-and-barriers-to-kidney-care-findings-from-a-global-survey
#8
REVIEW
Meaghan Lunney, Mona Alrukhaimi, Gloria E Ashuntantang, Aminu K Bello, Ezequiel Bellorin-Font, Mohammed Benghanem Gharbi, Vivekanand Jha, David W Johnson, Kamyar Kalantar-Zadeh, Rumeyza Kazancioglu, Michelle E Olah, Timothy Olusegun Olanrewaju, Mohamed A Osman, Yasin Parpia, Jeffrey Perl, Harun Ur Rashid, Ahmed Rateb, Eric Rondeau, Laura Sola, Irma Tchokhonelidze, Marcello Tonelli, Natasha Wiebe, Isaac Wirzba, Chih-Wei Yang, Feng Ye, Alexander Zemchenkov, Ming-Hui Zhao, Adeera Levin
An international survey led by the International Society of Nephrology in 2016 assessed the current capacity of kidney care worldwide. To better understand how governance and leadership guide kidney care, items pertinent to government priority, advocacy, and guidelines, among others, were examined. Of the 116 responding countries, 36% ( n  = 42) reported CKD as a government health care priority, which was associated with having an advocacy group (χ2 = 11.57; P  = 0.001). Nearly one-half (42%; 49 of 116) of countries reported an advocacy group for CKD, compared with only 19% (21 of 112) for AKI...
February 2018: Kidney International Supplements
https://read.qxmd.com/read/30675436/building-blocks-toward-sustainable-kidney-care-around-the-world-results-from-a-multinational-survey-by-the-international-society-of-nephrology
#9
EDITORIAL
Adeera Levin
No abstract text is available yet for this article.
February 2018: Kidney International Supplements
https://read.qxmd.com/read/30675435/novel-therapies-for-diabetic-kidney-disease
#10
REVIEW
David Z I Cherney, George L Bakris
Over the past 30 years there have been many complementary therapies developed to achieve glycemic control and have an impact on cardiovascular outcomes, as well as reduce the risk of microvascular disease. The 2 most notable new entries have been the sodium-glucose cotransporter 2 (SGLT2) inhibitors and the glucagon-like peptide-1 (GLP-1) agonists. Both these classes of agents have demonstrated reductions in cardiovascular event rates as well as reductions in blood pressure and weight. Moreover, while both have demonstrated a benefit in slowing nephropathy progression, the SGLT2 inhibitors appear to have a significantly greater effect compared with the GLP-1 agents...
January 2018: Kidney International Supplements
https://read.qxmd.com/read/30675434/cardiovascular-outcomes-in-diabetic-kidney-disease-insights-from-recent-clinical-trials
#11
REVIEW
Natalia A Rocha, Peter A McCullough
The prevalence of type 2 diabetes is catalyzing a pandemic in kidney disease, with ensuing cardiovascular complications. The effort to identify antidiabetic agents capable of promoting benefits that go beyond the bounds of glucose control has produced remarkable outcomes in recent cardiovascular outcomes trials in patients with type 2 diabetes mellitus, many of whom have diabetic kidney disease. Two novel antidiabetic drug classes, sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), improve cardiovascular outcomes in different ways, with SGLT2is reducing the risk of heart failure and cardiovascular death and GLP-1 RAs being associated with reduced risk of myocardial infarction and cardiovascular death...
January 2018: Kidney International Supplements
https://read.qxmd.com/read/30675433/diagnosis-of-diabetic-kidney-disease-state-of-the-art-and-future-perspective
#12
REVIEW
Frederik Persson, Peter Rossing
Approximately 20% to 40% of patients with type 1 or type 2 diabetes mellitus develop diabetic kidney disease. This is a clinical syndrome characterized by persistent albuminuria (> 300 mg/24 h, or > 300 mg/g creatinine), a relentless decline in glomerular filtration rate (GFR), raised arterial blood pressure, and enhanced cardiovascular morbidity and mortality. There is a characteristic histopathology. In classical diabetic nephropathy, the first clinical sign is moderately increased urine albumin excretion (microalbuminuria: 30-300 mg/24 h, or 30-300 mg/g creatinine; albuminuria grade A2)...
January 2018: Kidney International Supplements
https://read.qxmd.com/read/30675432/update-on-reducing-the-development-of-diabetic-kidney-disease-and-cardiovascular-death-in-diabetes
#13
EDITORIAL
George L Bakris
No abstract text is available yet for this article.
January 2018: Kidney International Supplements
https://read.qxmd.com/read/30681074/erratum-kidney-disease-improving-global-outcomes-kdigo-ckd-mbd-update-work-group-kdigo-2017-clinical-practice-guideline-update-for-the-diagnosis-evaluation-prevention-and-treatment-of-chronic-kidney-disease-mineral-and-bone-disorder-ckd-mbd-kidney-int-suppl
#14
https://read.qxmd.com/read/30675431/new-options-for-the-management-of-chronic-hyperkalemia
#15
REVIEW
Linda Fried, Csaba P Kovesdy, Biff F Palmer
Hyperkalemia is a frequently detected electrolyte abnormality that can cause life-threatening complications. Hyperkalemia is most often the result of intrinsic (decreased glomerular filtration rate; selective reduction in distal tubule secretory function; impaired mineralocorticoid activity; and metabolic disturbances, such as acidemia and hyperglycemia) and extrinsic factors (e.g., drugs, such as renin-angiotensin-aldosterone system inhibitors, and potassium intake). The frequent use of renin-angiotensin-aldosterone system inhibitors in patients who are already susceptible to hyperkalemia (e...
December 2017: Kidney International Supplements
https://read.qxmd.com/read/30675430/new-options-for-the-anemia-of-chronic-kidney-disease
#16
REVIEW
Daniel W Coyne, David Goldsmith, Iain C Macdougall
Anemia is a common complication of chronic kidney disease. Use of erythropoiesis-stimulating agents (ESA) has been a mainstay of treatment since 1990. A series of large trials demonstrated that ESAs have serious safety problems, including increasing cardiovascular and thrombotic events, and death. Analyses suggest high pharmacologic doses of ESAs, rather than the highly achieved hemoglobin, may mediate harm. Hypoxia-inducible factor (HIF) activators stimulate endogenous erythropoietin production and enhance iron availability...
December 2017: Kidney International Supplements
https://read.qxmd.com/read/30675429/global-kidney-health-atlas-gkha-design-and-methods
#17
REVIEW
Aminu K Bello, David W Johnson, John Feehally, David Harris, Kailash Jindal, Meaghan Lunney, Ikechi G Okpechi, Babatunde L Salako, Natasha Wiebe, Feng Ye, Marcello Tonelli, Adeera Levin
There has been considerable effort within individual countries to improve the care of patients with kidney disease. There has been no concerted attempt to summarize these efforts, and therefore little is known about structuring health systems to facilitate acute kidney injury and chronic kidney disease (CKD) care and integration with national and international noncommunicable disease strategies. As part of the "Closing the Gaps Initiative," the International Society of Nephrology will conduct for the first time a survey of the current state of global kidney care covering both acute kidney injury and CKD and present the results in a Global Kidney Health Atlas...
October 2017: Kidney International Supplements
https://read.qxmd.com/read/30675428/action-plan-for-optimizing-the-design-of-clinical-trials-in-chronic-kidney-disease
#18
REVIEW
Vlado Perkovic, Jonathan C Craig, Worawon Chailimpamontree, Caroline S Fox, Guillermo Garcia-Garcia, Mohammed Benghanem Gharbi, Meg J Jardine, Ikechi G Okpechi, Neesh Pannu, Benedicte Stengel, Katherine R Tuttle, Katrin Uhlig, Andrew S Levey
High-quality clinical trials are the cornerstone of evidence-based prevention and treatment of a disease, but nephrology has a strikingly weak base of such trials. Building the evidence base to improve outcomes for people with a kidney disease, therefore, requires both greater quantity and quality of clinical trials. To address these issues, we propose that we aim to enroll 30% of people with chronic kidney disease in trials by 2030. Goal 1: Strongly encourage and promote the conduct of clinical trials in people with chronic kidney disease to increase the number of clinical trials conducted...
October 2017: Kidney International Supplements
https://read.qxmd.com/read/30675427/the-establishment-and-validation-of-novel-therapeutic-targets-to-retard-progression-of-chronic-kidney-disease
#19
REVIEW
Carol Pollock, Anna Zuk, Hans-Joachim Anders, Mohammad Reza Ganji, David W Johnson, Bertram Kasiske, Robyn G Langham, Roberto Pecoits-Filho, Giuseppe Remuzzi, Jerome Rossert, Yusuke Suzuki, Tetsuhiro Tanaka, Robert Walker, Chih-Wei Yang, Joseph V Bonventre
The focus of this article is to define goals and resulting action plans that can be collectively embraced by interested stakeholders to facilitate new therapeutic approaches to mitigate chronic kidney disease progression. The specific goals include identifying druggable targets, increasing the capacity for preclinical and early clinical development, broadening the availability of new therapeutic approaches, and increasing investment in the development of new therapies to limit chronic kidney disease. Key deliverables include the establishment of new regional, national, and global consortia; development of clinical trial networks; and creation of programs to support the temporary mutual movement of scientists between academia and the biotechnology and pharmaceutical sector...
October 2017: Kidney International Supplements
https://read.qxmd.com/read/30675426/complications-of-chronic-kidney-disease-current-state-knowledge-gaps-and-strategy-for-action
#20
REVIEW
Aminu K Bello, Mona Alrukhaimi, Gloria E Ashuntantang, Shakti Basnet, Ricardo C Rotter, Walter G Douthat, Rumeyza Kazancioglu, Anna Köttgen, Masaomi Nangaku, Neil R Powe, Sarah L White, David C Wheeler, Orson Moe
The International Society of Nephrology has adopted a proactive approach to defining the current state of kidney care and unmet needs through a multifaceted Closing the Gaps initiative. As part of this initiative, the International Society of Nephrology convened a meeting of experts to develop an approach to tackle acute kidney injury and chronic kidney disease (CKD). This manuscript expands on the recently published International Society of Nephrology CKD Roadmap and reports on the discussions of the working group assigned to the task of reviewing the global impact of complication of CKD...
October 2017: Kidney International Supplements
journal
journal
47776
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"